`BIB_320`

Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, et al. (Blank C, Long G, MIA Sydney + NKI Amsterdam + multicentre). NADINA trial: Neoadjuvant nivolumab plus ipilimumab in resectable stage III melanoma. NEJM 2024;391(18):1696–1708 + ESMO 2025 24-month update (LBA42 Annals of Oncology Oct 2024). NCT04949113. Key numbers: 24-mo EFS 77.3% neoadjuvant vs 55.7% adjuvant (HR 0.40); 24-mo DMFS 82.8% vs 63.9% (HR 0.43). pCR 95.1% 24-mo RFS, pNR 48.4%. Australia first country to publicly subsidise neoadjuvant ICI at Stage III (Aug 2025) on basis of this trial. [Tasks: 18, 19, 19b] Tier: 1 (NEJM ph…

Evidence grade: A
Tier: 1 (NEJM phase III)
Cited by tasks: 18, 19, 19b
Identifiers: —

Full extracted findings & patient-implication analysis: bibliography/BIB_320/findings.md (research corpus). This page is a short context summary — not individualised medical advice.